Long-term Study of KAD-1229 in Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as
combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show
inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.